Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea's Celltrion Develops Universal "Super Flu-Antibody Therapy"

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean biopharma company Celltrion has developed a human monoclonal antibody product that could be effective against multiple influenza viruses such as the pandemic H1N1 and the H5N1 avian influenza virus

You may also be interested in...

Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions

SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News

Korea FDA Gears Up To Release Biosimilar Guidelines Modeled After EU Rules

SEOUL - South Korea's FDA is getting ready to release - possibly by the end of May - an initial version of guidelines for approval and registration of biosimilars modeled after European Union rules. The guidelines will wrap up KFDA's year-long drive to set up a regulatory framework for the new breed of follow-on biologics

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts